TXNDC5 and cystic fibrosis: Suppress the expression of TXNDC5 therefore provides a new therapeutic target for the treatment of CF, in contrast to traditional therapeutic modalities, including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs) and mineralocorticoid receptor antagonist (MRA) (101–103).